XML 53 R61.htm IDEA: XBRL DOCUMENT v3.19.3
Debt Obligations - Additional Information (Detail) - USD ($)
$ in Millions
1 Months Ended 9 Months Ended
Jul. 31, 2019
Sep. 30, 2019
Nov. 15, 2019
Jun. 30, 2019
Apr. 30, 2019
Dec. 31, 2018
Nov. 30, 2015
Debt Instrument [Line Items]              
Revolving credit facility         $ 2,300   $ 3,000
Senior notes   $ 26,417       $ 28,483  
Debt instrument redeemed amount   $ 2,300          
Long term debt currency portion USD   68.00%          
Long term debt currency portion EUR   29.00%          
Long term debt currency portion CHF   3.00%          
'Senior notes USD 1,700 million [Member]              
Debt Instrument [Line Items]              
Senior notes [1]           $ 1,700  
Weighted average interest rate 1.70% 1.70% [1]          
Repayments of short-term debt $ 1,556            
'Senior notes USD 1,700 million [Member] | Senior Notes [Member]              
Debt Instrument [Line Items]              
Senior notes       $ 1,700      
Debt instrument redeemed amount       $ 144      
Weighted average interest rate       1.70%      
Revolving Credit Facility [Member]              
Debt Instrument [Line Items]              
Debt Instrument, Covenant Description   The net debt to EBITDA ratio limit is 6.25x through December 31, 2019, gradually declines to 5.75x in the third and fourth quarters of 2020, and continues to gradually decline over the remaining term of the RCF.          
Long Term Debt Payable Under Revolving Credit Facility   $ 100          
Revolving Credit Facility [Member] | Subsequent Event [Member]              
Debt Instrument [Line Items]              
Long Term Debt Payable Under Revolving Credit Facility     $ 0        
[1] During the first six months of 2019, Teva repurchased and canceled approximately $144 million principal amount of its $1,700 million 1.7% senior notes due in July 2019. In July 2019, Teva repaid at maturity $1,556 million of its 1.7% senior notes.